MBL949, a GDF15 receptor agonist with extended half-life, showed promising weight loss effects in nonclinical species but minimal efficacy in humans during a 14-week phase 2 trial. Supported by AMR Clinical sites, the study evaluated subcutaneous biweekly dosing in overweight and obese participants. MBL949 was generally well tolerated, with GI events as the most common adverse effects. The data support continued evaluation of dosing strategies and patient selection.
Read this publication to explore:
- Weight loss and safety outcomes from phase 1 and 2 trials
- Pharmacokinetics and dosing rationale for MBL949
- Key differences in response between nonclinical and human data